Ambu A/S
OTC:AMBFF
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| DK |
|
Ambu A/S
CSE:AMBU B
|
19.3B DKK |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.4B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
129.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
109.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.5B EUR |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
51.2B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
49.9B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.5B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36B USD |
Loading...
|
Market Distribution
| Min | -2 199.8% |
| 30th Percentile | 26.7% |
| Median | 45.7% |
| 70th Percentile | 65.9% |
| Max | 1 637.7% |
Other Profitability Ratios
Ambu A/S
Glance View
Ambu A/S, a Danish company rooted in innovation, has carved a niche in the global healthcare sector through its specialized medical devices. Founded in 1937, Ambu started with a simple mission of improving patient care and has stayed true to that vision by continuously advancing their portfolio. The company's journey began with the invention of the resuscitator bag, a revolutionary product that remains a staple in emergency and hospital settings today. Over the years, Ambu has focused strategically on three main segments: Anesthesia, Patient Monitoring & Diagnostics, and Visualisation, each playing a crucial role in the broader healthcare ecosystem. These segments allow Ambu to develop devices that enhance diagnostic procedures, improve safety, and increase efficiency in medical settings, ultimately saving lives and optimizing healthcare delivery. Ambu’s business model capitalizes primarily on innovation-driven sales, with a strong emphasis on disposable medical devices which are gaining popularity due to hygiene concerns and regulatory trends favoring single-use technologies. These products include their flagship single-use endoscopes, marketed under the brand name "Ambu aScope," which significantly reduce the risk of cross-contamination while providing high-quality diagnostic images. The company's revenue model is built on a B2B approach, dealing directly with hospitals, clinics, and other healthcare providers, ensuring a steady flow of sales through long-term contracts and partnerships. Through constant reinvestment into R&D and strategic acquisitions, Ambu sustains its market leadership, driving growth by addressing the evolving needs of the healthcare industry and setting standards in patient care solutions globally.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Ambu A/S is 60.2%, which is above its 3-year median of 58.5%.
Over the last 3 years, Ambu A/S’s Gross Margin has increased from 58.1% to 60.2%. During this period, it reached a low of 56.4% on Mar 31, 2023 and a high of 60.3% on Mar 31, 2025.